Hjem › Major depresjon › Florida › Tampa
Kliniske studier for Major depresjon i Tampa, FL
17 studier for Major depresjon søker deltakere på steder i og rundt Tampa (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
RekruttererFase 2
- IPTB Clinical Research, Tampa
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
RekruttererFase 3
- K2 Medical Research Tampa, Tampa
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
RekruttererFase 3
- K2 Medical Research (Tampa), Tampa
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
RekruttererFase 3
- K2 Medical Research - Tampa, Tampa
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
RekruttererFase 3
- IPTB Clinical Research, Tampa
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
RekruttererFase 3
- Interventional Psychiatry of Tampa Bay, Tampa
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
RekruttererFase 3
- Psych Me Medical Research Inc, Tampa
- Interventional Psychiatry of Tampa Bay, Tampa
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
RekruttererFase 2
- K2 Medical Research - Tampa, Tampa
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RekruttererFase 4
- Neurocrine Clinical Site, Tampa
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
RekruttererFase 2
- Draig Clinical Site, Tampa
- Draig Clinical Site, Tampa
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
Rekrutterer
- USF Health, Tampa
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RekruttererFase 3
- Neurocrine Clinical Site, Tampa
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RekruttererFase 3
- Neurocrine Clinical Site, Tampa
- Neurocrine Clinical Site, Tampa
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RekruttererFase 3
- Neurocrine Clinical Site, Tampa
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
RekruttererFase 2
- University of South Florida, Psychiatry and Behavioral Neurosciences, Tampa
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
RekruttererFase 2
- Autobahn Site #148, Tampa
Study of ALTO-300 in MDD
RekruttererFase 2
- Site 221, Tampa
Major depresjon-studier i andre byer
- New York City, NY36 studier
- Boston, MA31 studier
- Atlanta, GA25 studier
- Philadelphia, PA23 studier
- Orlando, FL19 studier
- Miami, FL18 studier
- Chicago, IL17 studier
- San Diego, CA16 studier
- Houston, TX16 studier
- Little Rock, AR14 studier
- Austin, TX13 studier
- Las Vegas, NV13 studier
Andre studier i Tampa
- Ikke-småcellet lungekreft51 studier
- Brystkreft43 studier
- Kreft (alle typer)39 studier
- Kolorektal kreft34 studier
- Akut myelogen leukemi29 studier
- Metastatisk kreft29 studier
- Lungekreft29 studier
- Pankreaskreft26 studier
- Eggstokkreft21 studier
- Melanom19 studier
- Myelodysplastiske syndromer19 studier
- Prostatakreft18 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.